

Supplemental Information

SUPPLEMENTAL TABLE 3 Diagnostic Codes

	Encounters With ICD-9 Codes (<i>n</i> = 3201), <i>n</i> (%)	Encounters With ICD-10 Codes (<i>n</i> = 1197), <i>n</i> (%)
Primary diagnosis of a depressive disorder		
Major depressive disorder (296.2x, 296.3x, 311; F32–F33.9)	1432 (44.7)	578 (48.3)
Dysthymic or persistent mood disorder (300.4; F34–F34.9)	14 (0.4)	17 (1.4)
Primary diagnosis of a disruptive disorder		
Attention-deficit/hyperactivity disorder (314.xx; F90–F90.9)	84 (2.6)	30 (2.5)
Oppositional defiant disorder or conduct disorder (312.xx, 313.81; F91–F91.9)	802 (25.1)	234 (19.5)
Any coded autistic disorder (299.00, 299.01; F84.0)	333 (10.4)	158 (13.2)
Any coded pervasive developmental disorders (299.00, 299.01, 299.10, 299.80, 299.81, 299.90, 315.00, 315.02, 315.09, 315.1, 315.2, 315.31, 315.32, 315.34, 315.35, 315.39, 315.4, 315.5, 315.8, 315.9, 330.8; F80.xx, F81.xx, F82, F84.0, F84.2, F84.3, F84.5, F84.8, F84.9, F88, F89)	436 (13.6)	196 (16.4)
Any coded intellectual disability (317, 318.0–318.2, 319; F70–F79)	122 (3.8)	59 (4.9)
Any coded medical disorder (not 290–319, V code; not F01–F99, Z code)	1558 (48.7)	559 (46.7)
Primary diagnosis of an eating disorder (262, 307.1, 263.1, 263.8, 263.9, 307.1, 307.5, 307.51, 307.54, 307.59, 427.81, 427.89, 783.21; E43, E44.0, E46, F50.00, F50.01, F50.02, R00.1, E44.1, F50.2, F50.8, F50.89, F50.9, R63.4)	57 (1.8)	18 (1.5)

ICD-9, *International Classification of Diseases, Ninth Revision*; ICD-10, *International Classification of Diseases, 10th Revision*.

SUPPLEMENTAL TABLE 4 Antipsychotics**Antipsychotics**

Abilify (aripiprazole)
 Abilify Maintena injection (aripiprazole extended release)
 Aripiprazole (Abilify)
 Aripiprazole extended release (Abilify Maintena injection)
 Asenapine (Saphris)
 Chlorpromazine (Ormazine, Thorazine)
 Clozapine (Clozaril, FazaClo)
 Clozaril (clozapine, FazaClo)
 Compro (prochlorperazine)
 Eskalith (lithium, Lithonate, Lithotabs)
 Eskalith CR (lithium slow or extended release, Lithobid)
 Etrafon (perphenazine and amitriptyline, Triavil)
 Fanapt (iloperidone)
 FazaClo (clozapine, Clozaril)
 Fluphenazine (Permitil, Prolixin)
 Geodon (ziprasidone)
 Haldol (haloperidol)
 Haldol Decanoate injection (haloperidol decanoate extended release)
 Haloperidol (Haldol)
 Haloperidol decanoate extended release (Haldol Decanoate injection)
 Iloperidone (Fanapt)
 Invega (paliperidone, Invega Sustenna)
 Invega Sustenna (Invega, paliperidone)
 Latuda (lurasidone)
 Lithium (Eskalith, Lithonate, Lithotabs)
 Lithium slow or extended release (Eskalith CR, Lithobid)
 Lithobid (lithium slow or extended release, Eskalith CR)
 Lithonate (Eskalith, lithium, Lithotabs)
 Lithotabs (Eskalith, lithium, Lithonate)
 Loxapine (Loxitane)
 Loxitane (loxapine)
 Lurasidone (Latuda)
 Mellaril (thioridazine)
 Navane (thiothixene)
 Olanzapine (Zydis Solutab, Zyprexa)
 Olanzapine extended release (Zyprexa Relprev injection)
 Olanzapine and fluoxetine (Symbyax)
 Orap (pimozide)
 Ormazine (chlorpromazine, Thorazine)
 Paliperidone (Invega, Invega Sustenna)

SUPPLEMENTAL TABLE 4 Continued**Antipsychotics**

Permitil (fluphenazine, Prolixin)
 Perphenazine (Trilafon)
 Perphenazine and amitriptyline (Etrafon, Triavil)
 Pimozide (Orap)
 Prochlorperazine (Compro)
 Prolixin (fluphenazine, Permitil)
 Quetiapine (Seroquel)
 Quetiapine extended release (Seroquel XR)
 Risperdal (risperidone)
 Risperdal Consta injection (risperidone extended release)
 Risperidone (Risperdal)
 Risperidone extended release (Risperdal Consta injection)
 Saphris (asenapine)
 Seroquel (quetiapine)
 Seroquel XR (quetiapine extended release)
 Stelazine (trifluoperazine)
 Symbyax (olanzapine and fluoxetine)
 Thioridazine (Mellaril)
 Thiothixene (Navane)
 Thorazine (chlorpromazine, Ormazine)
 Triavil (perphenazine and amitriptyline, Etrafon)
 Trifluoperazine (Stelazine)
 Trilafon (perphenazine)
 Ziprasidone (Geodon)
 Zydis Solutab (olanzapine, Zyprexa)
 Zyprexa (olanzapine, Zydis Solutab)
 Zyprexa Relprev injection (olanzapine extended release)

SUPPLEMENTAL TABLE 5 ACA Regression Analysis: Adjusted Association Between LOS and 30-d ED Return Visits and 30-d Inpatient Readmissions

	30-d ED Return Visits OR (95% CI)	30-d Inpatient Readmissions OR (95% CI)
Model 1: No EMM ^a		
LOS (d)	0.98 (0.96 to 0.99)	1.00 (0.99 to 1.01)
Model 2: EMM by diagnosis ^b		
LOS among those with neither a depressive nor a disruptive disorder	0.98 (0.96 to 1.00)	1.00 (0.99 to 1.02)
LOS among those with a depressive disorder	1.01 (0.97 to 1.04)	1.02 (0.99 to 1.05)
LOS among those with a disruptive disorder	0.94 (0.90 to 0.99)	0.95 (0.90 to 1.02)
Model 3: EMM by disease severity ^c		
LOS among those not discharged on an antipsychotic	0.97 (0.94 to 0.998)	0.99 (0.97 to 1.02)
LOS among those discharged on an antipsychotic	0.98 (0.96 to 1.00)	1.00 (0.98 to 1.02)
Model 4: EMM by payer ^d		
LOS among those not insured by Medicaid	0.98 (0.96 to 1.01)	1.01 (0.99 to 1.03)
LOS among those insured by Medicaid	0.97 (0.95 to 0.997)	0.99 (0.97 to 1.01)
Model 5: EMM by time period ^e		
LOS preimplementation	0.97 (0.93 to 1.01)	1.00 (0.97 to 1.03)
LOS during implementation	1.00 (0.97 to 1.03)	1.00 (0.97 to 1.03)
LOS post implementation	0.98 (0.96 to 1.00)	1.00 (0.99 to 1.02)

OR, odds ratio.

^a Adjusted for age, race and/or ethnicity, developmental delay, intellectual disability, diagnosis, disease severity, and payer.

^b Adjusted for age, race and/or ethnicity, developmental delay, intellectual disability, disease severity, and payer.

^c Adjusted for age, race and/or ethnicity, developmental delay, intellectual disability, diagnosis, and payer.

^d Adjusted for age, race and/or ethnicity, developmental delay, intellectual disability, diagnosis, and disease severity.

^e Adjusted for age, race and/or ethnicity, developmental delay, intellectual disability, diagnosis, disease severity, and payer.